Ajanta Pharma Limited (AJANTPHARM) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 25, 2026 3 min read

Ajanta Pharma enters Q1 FY27 results looking to maintain its momentum as a branded-generics leader following a record-breaking FY26 where revenue crossed Rs. 5,000 Cr. Investors will be closely watching the company's ability to sustain its mid-teen revenue growth guidance while navigating margin pressures from currency volatility and structural price erosion in the US generics market.

Quick Details

Results date	July 30, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 1,422 Cr
Previous quarter PAT	Rs. 267 Cr
Previous quarter EBITDA margin	23%
Market cap	Rs. 42,097.06 Cr
CMP	Rs. 3369.5

Ajanta Pharma Limited Q1 Results Date and Time

The board meeting is scheduled for 2026-07-30 to consider the audited financial results and recommend dividend for FY2026.

What to expect from Ajanta Pharma Limited's Q1 FY27 results

Ajanta Pharma's Q1 performance will be measured against its full-year guidance of high-teen revenue growth, with the India business acting as a primary anchor given its 30% revenue contribution. While the US generics segment delivered 49% growth in FY26, management has recalibrated expectations to mid-single-digit growth for FY27, making the Q1 trajectory a critical test of this moderation. Adjusted EBITDA margins are expected to remain near the 27% band, though reported profitability will likely face a 150-200 bps headwind from MTM forex losses due to the rupee trading in the 95-96 band against the USD. The upcoming call is expected to provide long-awaited clarity on the semaglutide commercialization timeline and the remediation status of the five FDA observations received at the Paithan facility in April 2026.

Key Things To Watch

Performance vs Guidance Tracking

Overall Revenue Growth — High-teen (16-18%) by FY27 — On track
EBITDA Margin — 27% (+/-1%) by FY27 — On track
US Generics Growth — Mid-single-digit by FY27 — Monitoring

Operating metric trajectory

India Business — Outpacing IPM growth with 12-15% range target for Q1
US Generics — Deceleration expected from prior year's 36% Q1 trajectory
Asia/Africa Branded — Monitoring for turnaround after -1% FY26 growth

Strategic execution / capex updates

Semaglutide — Filing status and market entry plans pending disclosure
Capex — FY27 guidance of Rs. 400 Cr vs Rs. 300 Cr in FY26
MR Expansion — Planned addition of 250-300 MRs in India and 130-150 in Asia/Africa

Risks and headwinds to monitor

Forex Volatility — MTM losses estimated at Rs. 30-50 Cr due to rupee depreciation
Regulatory — Paithan facility FDA inspection status following 5 observations
Supply Chain — Elevated freight costs due to Red Sea shipping disruptions

Frequently Asked Questions

How did Ajanta Pharma's India business perform in FY26?

The India business generated Rs. 1,654 Cr in revenue, achieving 14% growth and outperforming the broader IPM which grew at 10%. This was supported by a 3.6% volume increase, a 4.8% price contribution, and 4.7% from new launches.

What is the status of Ajanta Pharma's US generics growth?

After an exceptional 49% growth in FY26, management has guided for mid-single-digit growth in FY27 to account for structural price erosion. The upcoming call will clarify if Q1 performance aligns with this moderated outlook.

Why is there a difference between reported and adjusted EBITDA margins?

The difference is primarily driven by mark-to-market (MTM) foreign exchange movements recorded under other expenses. Management advises focusing on the adjusted EBITDA margin, which excludes these forex fluctuations, to better reflect operational performance.